The Federal Trade Commission is cracking down on marketers of mobile apps for making unsubstantiated claims about their ability to accurately analyze moles for symptoms of melanoma.

According to FTC, marketers of MelApp and Mole Detective “deceptively claimed the apps accurately analyzed melanoma risk and could assess such risk in early stages” and also ”lacked adequate evidence to support such claims.” While the marketers agreed to settlements that bar them from continuing to make such scientifically unsupported claims, the regulatory agency said it is pursuing charges against two additional marketers of Mole Detective who did not agree to settle.

Register or login for access to this item and much more

All Health Data Management content is archived after seven days.

Community members receive:
  • All recent and archived articles
  • Conference offers and updates
  • A full menu of enewsletter options
  • Web seminars, white papers, ebooks

Don't have an account? Register for Free Unlimited Access